Statins Suppress Ebola Virus Infectivity by Interfering with Glycoprotein Processing

Details

• Alternative Title:
  mBio
• Personal Author:
  Shrivastava-Ranjan, Punya ; Flint, Mike ; Bergeron, Éric ; McElroy, Anita K. ; Chatterjee, Payel ; Albariño, César G. ; Nichol, Stuart T. ; Spiropoulou, Christina F.
• Description:
  Ebola virus (EBOV) infection is a major public health concern due to high fatality rates and limited effective treatments. Statins, widely used cholesterol-lowering drugs, have pleiotropic mechanisms of action and were suggested as potential adjunct therapy for Ebola virus disease (EVD) during the 2013-2016 outbreak in West Africa. Here, we evaluated the antiviral effects of statin (lovastatin) on EBOV infection | Statin treatment decreased infectious EBOV production in primary human monocyte-derived macrophages and in the hepatic cell line Huh7. Statin treatment did not interfere with viral entry, but the viral particles released from treated cells showed reduced infectivity due to inhibition of viral glycoprotein processing, as evidenced by decreased ratios of the mature glycoprotein form to precursor form. Statin-induced inhibition of infectious virus production and glycoprotein processing was reversed by exogenous mevalonate, the rate-limiting product of the cholesterol biosynthesis pathway, but not by low-density lipoprotein. Finally, statin-treated cells produced EBOV particles devoid of the surface glycoproteins required for virus infectivity. Our findings demonstrate that statin treatment inhibits EBOV infection and suggest that the efficacy of statin treatment should be evaluated in appropriate animal models of EVD.| Treatments targeting Ebola virus disease (EVD) are experimental, expensive, and scarce. Statins are inexpensive generic drugs that have been used for many years for the treatment of hypercholesterolemia and have a favorable safety profile. Here, we show the antiviral effects of statins on infectious Ebola virus (EBOV) production. Our study reveals a novel molecular mechanism in which statin regulates EBOV particle infectivity by preventing glycoprotein processing and incorporation into virus particles. Additionally, statins have anti-inflammatory and immunomodulatory effects. Since inflammation and dysregulation of the immune system are characteristic features of EVD, statins could be explored as part of EVD therapeutics.
• Subjects:
  Antiviral Agents Cell Line Ebolavirus Hemorrhagic Fever, Ebola Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors Protein Processing, Post-Translational Viral Envelope Proteins Virulence Virus Internalization
• Source:
  mBio. 9(3).
• Pubmed ID:
  29717011
• Pubmed Central ID:
  PMC5930306
• Document Type:
  Journal Article
• Funding:
  K08 AI119448/AI/NIAID NIH HHS/United States
• Volume:
  9
• Issue:
  3
• Collection(s):
  CDC Public Access
• Main Document Checksum:
  urn:sha256:c59974c51c712ed0db49c2b783c88357bbb6e228a392797003f316016795dcc7
• Download URL:
  https://stacks.cdc.gov/view/cdc/53865/cdc_53865_DS1.pdf
• File Type:
  [PDF - 2.43 MB ]